1 of 1
Story summary
- On December 19, 2025, the U.S. government announced Medicare pilots, GUARD and GLOBE, to reduce out-of-pocket drug costs by benchmarking rebates to international prices, launching in 2026 and 2027.
- President Donald Trump announced nine pharmaceutical companies will adopt a most-favored-nation pricing policy for Medicare and Medicaid.
- Price reductions occurred for Amgen's Repatha and Gilead's Epclusa, dropping to $239 and $2,425 respectively.
- He plans to negotiate with insurers to reduce costs.
